Guido Reifenberger
Impact in
- Genetics top 0.01%
- Glioma Diagnosis and Treatment
- Cancer Research top 0.02%
- MicroRNA in disease regulation
- Cancer, Hypoxia, and Metabolism
Papers in
- Genetics 237
- Glioma Diagnosis and Treatment 234
-
- Epigenetics and DNA Methylation 45
- Chromatin Remodeling and Cancer 25
- Co-authors
- Andreas von Deimling (53 shared papers)David N. Louis (15 shared papers)Arie Perry (15 shared papers)David W. Ellison (6 shared papers)Webster K. Cavenee (2 shared papers)Paul Kleihues (2 shared papers)Otmar D. Wiestler (18 shared papers)Michael Weller (104 shared papers)
- Journals
- Acta Neuropathologica (28 papers)Neuro-Oncology (27 papers)Journal of Clinical Oncology (27 papers)Brain Pathology (18 papers)International Journal of Cancer (16 papers)
- Partner nations
- GermanySwitzerlandUnited States
In The Last Decade
Guido Reifenberger
357 papers receiving 49.6k citations
Guido Reifenberger's Hit Papers
Peers
Comparison fields: 5 of 177
- Genetics 27.4k
- Cancer Research 10.3k
- Neurology 5.8k
- Molecular Biology 16.4k
- Radiology, Nuclear Medicine and Imaging 4.8k
Countries citing papers authored by Guido Reifenberger
This map shows the geographic impact of Guido Reifenberger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guido Reifenberger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guido Reifenberger more than expected).
Fields of papers citing papers by Guido Reifenberger
This network shows the impact of papers produced by Guido Reifenberger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guido Reifenberger. The network helps show where Guido Reifenberger may publish in the future.
Co-authors
The 25 scholars most cited alongside Guido Reifenberger, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 368 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary Hit paper breakdown → | 2016 | 11461 |
| 2 | The 2021 WHO Classification of Tumors of the Central Nervous System: a summary Hit paper breakdown → | 2021 | 6722 |
| 3 | The WHO Classification of Tumors of the Nervous System Hit paper breakdown → | 2002 | 1605 |
| 4 | Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas Hit paper breakdown → | 2009 | 924 |
| 5 | Glioma Hit paper breakdown → | 2015 | 833 |
| 6 | Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial Hit paper breakdown → | 2012 | 819 |
| 7 | Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma Hit paper breakdown → | 2011 | 792 |
| 8 | Long-term survival with glioblastoma multiforme Hit paper breakdown → | 2007 | 703 |
| 9 | Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas Hit paper breakdown → | 2010 | 661 |
| 10 | NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide Hit paper breakdown → | 2009 | 619 |
| 11 | MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Hit paper breakdown → | 2009 | 612 |
| 12 | EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma Hit paper breakdown → | 2014 | 589 |
| 13 | cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV” Hit paper breakdown → | 2018 | 581 |
| 14 | Glioblastoma: pathology, molecular mechanisms and markers Hit paper breakdown → | 2015 | 534 |
| 15 | Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Hit paper breakdown → | 1994 | 517 |
| 16 | Advances in the molecular genetics of gliomas — implications for classification and therapy Hit paper breakdown → | 2016 | 506 |
| 17 | Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network Hit paper breakdown → | 2009 | 498 |
| 18 | Molecular targeted therapy of glioblastoma Hit paper breakdown → | 2019 | 494 |
| 19 | MGMT testing—the challenges for biomarker-based glioma treatment Hit paper breakdown → | 2014 | 418 |
| 20 | CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. | 1994 | 403 |
About Guido Reifenberger
Guido Reifenberger is a scholar working on Genetics, Molecular Biology, Cancer Research, Neurology and Pulmonary and Respiratory Medicine, having authored 368 papers that have together received 50.6k indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (234 papers), Epigenetics and DNA Methylation (45 papers), Brain Metastases and Treatment (33 papers), Neuroblastoma Research and Treatments (29 papers), Cancer Genomics and Diagnostics (26 papers), Chromatin Remodeling and Cancer (25 papers), MicroRNA in disease regulation (24 papers) and Meningioma and schwannoma management (24 papers). The work is most often cited by research in Genetics (27.4k citations), Cancer Research (10.3k citations), Neurology (5.8k citations), Molecular Biology (16.4k citations) and Radiology, Nuclear Medicine and Imaging (4.8k citations). Guido Reifenberger has collaborated with scholars based in Germany, Switzerland and United States. Frequent co-authors include Andreas von Deimling, David N. Louis, Arie Perry, David W. Ellison, Webster K. Cavenee, Paul Kleihues, Otmar D. Wiestler, Michael Weller, Hiroko Ohgaki and Dominique Figarella-Branger. Their work appears in journals such as Acta Neuropathologica, Neuro-Oncology, Journal of Clinical Oncology, Brain Pathology and International Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.